FASLG elevation

News alerts, weekly reports and conference planners

Entrez ID:

FASLG elevation	Head and Neck Cancer	FASLG elevation	Head and Neck Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
FASLG elevation	Pancreatic Ductal Adenocarcinoma	FASLG elevation	Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
FASLG elevation	Pancreatic Ductal Adenocarcinoma	FASLG elevation	Pancreatic Ductal Adenocarcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3

Associations